AI Based Drug Discovery:
Reshaping the Pharmaceutical Frontier

This report offers an in-depth, data-backed analysis of the AI-based drug discovery landscape, covering market structure, technology trends, patent activity, competitive positioning, and strategic outlook, built for teams that need more than a surface-level overview to make informed decisions.

🔓 Unlock the Long Report · $1,500 See what's inside
One-time payment · Instant PDF access · No subscription
$2.6B
Cost per approved molecule
9,500+
AI drug discovery patents analysed
14×
Growth in annual filings, 2017 → 2025
$13.77B
Projected market size by 2033
Short report vs. Long report

You've read the summary. Here's what it left out.

The short report gives you the headline story. The long report gives you the full analysis, the underlying datasets, jurisdictional breakdowns, and named-company benchmarking that attorneys and strategy teams actually need to brief clients or leadership.

What you get
Short Report
Long Report
Headline market & patent-filing trends
✓
✓
Full patent dataset breakdown (9,500+ filings, by assignee, year, jurisdiction)
✕
✓
Top patent-holder league table with filing depth & strategy notes
✕
✓
Jurisdiction-by-jurisdiction competitive analysis (US · China · India & more)
✕
✓
Technology taxonomy & capability-maturity scoring
Summary only
✓
Reconciled market-size models & growth forecasts
One figure cited
✓
Clinical pipeline tracking & AI-discovered candidate analysis
✕
✓
Named-company deal, funding & licensing intelligence
✕
✓
Strategic playbook: white-space, IP risk & 2026–2030+ outlook
Headings only
✓

The numbers shaping the next wave of AI drug discovery

A sample of the findings inside the long report, each backed by sourced, citable data your team can put directly into a memo.
9,500+

AI Drug Discovery Patents Analysed

A comprehensive review of global patent filings across the full AI drug discovery innovation landscape.

120+ deals

AI-Pharma Platform Licensing Deals

Worth $12B+ in disclosed value, reflecting the surge in pharma-AI collaboration activity.

$3–8B

Estimated 2026 AI Drug Discovery Market

A wide range that reflects differing methodologies across current market-sizing models.

34% CAGR

Foundational-AI Patent Filings Since 2020

Shows accelerating IP activity around the core AI architectures underpinning discovery tools.

7,756 records

Concentrated Around Discovery & Target Biology

Highlights where innovation and filing activity are most densely clustered today.

China 5,357

Vs. US: 2,249 and India: 501 Patent Filings

Marks the shift toward a multi-polar global competition for AI drug discovery IP.

Designed for Decision-Makers Across AI Drug Discovery

IP

Patent Attorneys

Freedom-to-operate context and assignee-level filing intelligence for client advisory.

R&D

Pharma R&D Leaders

Capability-maturity benchmarking to prioritise where AI actually moves the pipeline needle.

$

Investors & Analysts

Reconciled market models and named-company positioning for diligence and thesis-building

GC

Innovation & IP Strategy Teams

A board-ready narrative on where to file, partner, or acquire before the 2027–2030 conversion wave.

Frequently Asked Questions

How is this different from the short report on the website?

The short report is a focused summary. The long report includes the underlying patent dataset breakdowns, the complete top-20 assignee table, jurisdictional deep-dives, and an editable chart pack, the material teams actually cite in memos and board decks.

What format is the report delivered in?

A 72-page PDF, delivered instantly to the email used at checkout, along with a companion chart pack for internal presentations.

Is the data sourced and citable?

Yes. Every figure is drawn from Intelacia’s original patent analysis and cross-referenced against major market-research houses, with sourcing notes included in the report.

AI Based Drug Discovery: Long Report · $1,500